North America Bloodstream Infection Testing Market Size | Companies
The North America bloodstream infection testing market size was exhibited at USD 319.58 million in 2023 and is projected to hit around USD 464.04 million by 2033, growing at a CAGR of 3.8% during the forecast period 2024 to 2033.
| Report Coverage | Details |
| Market Size in 2024 | USD 331.72 Million |
| Market Size by 2033 | USD 464.04 Million |
| Growth Rate From 2024 to 2033 | CAGR of 3.8% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Product, Sample Type, Technology, End-user, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Country scope | U.S.; Canada |
| Key Companies Profiled | bioMérieux SA; BD; Cepheid; Seegene Inc.; Abbott; F. Hoffmann-La Roche Ltd.; Siemens Healthcare Limited; Luminex Corporation; Bruker; Accelerate Diagnostics, Inc. |
Increasing demand for advanced bloodstream infection testing methods and a rising number of CROs and forensic and research laboratories are among the major factors expected to drive growth in the bloodstream infection testing market. Moreover, the introduction of culture-independent tests holds significant promise in improving patient management with bloodstream infections (BSI) as these methods can reduce the time required for test results and enhance their accuracy. Furthermore, the high prevalence of STIs and tuberculosis in the region is also anticipated to propel the bloodstream infection testing market growth.
According to CDC data, reported cases of STIs such as chlamydia, syphilis, and gonorrhea increased between 2020 and 2021. According to the survey, more than 2.5 million cases were reported during this period and gonorrhea rates rose by over 4%, while syphilis rates surged, increasing by nearly 32% for combined stages of the infection. Congenital syphilis cases also saw a significant 32% increase, leading to 220 stillbirths and infant deaths. Chlamydia rates increased by approximately 4%, as per the report.
The U.S. bacterial infection testing market has witnessed significant trends in recent years. With increasing awareness about healthcare-associated infections and the rise in drug-resistant bacteria, there has been a growing demand for accurate and rapid diagnostic tests. Molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), have gained prominence due to their high sensitivity and specificity.
Additionally, there is a shift towards point-of-care testing, allowing for faster diagnosis and treatment decisions. The market also is seeing a rising adoption of automated systems and integrated platforms, streamlining the testing process and improving efficiency. Overall, the U.S. bacterial infection testing market is expected to continue its growth trajectory fueled by technological advancements and the need for prompt and accurate diagnostics.
Another significant trend in the U.S. bacterial infection testing market is the increasing adoption of MALDI-TOF mass spectrometry. MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) is a powerful technology that enables rapid identification of bacteria and their antibiotic resistance profiles. It offers advantages such as high accuracy, speed, and cost-effectiveness compared to traditional culture-based methods. With its ability to identify a wide range of bacterial species within minutes, MALDI-TOF has become an essential tool in clinical laboratories for diagnosing bacterial infections. Its widespread implementation is driven by the need for timely and targeted treatment decisions, especially in sepsis and antibiotic-resistant infections.
As a result, the U.S. bacterial infection testing market is witnessing a growing demand for MALDI-TOF mass spectrometry platforms. For instance, in February 2023, Bruker Corporation introduced the timsTOF MALDI PharmaPulse system, an advanced high-end solution designed for unbiased and efficient high-throughput screening (HTS) and ultra-high-throughput screening (uHTS) utilizing label-free mass spectrometry. This innovative system enables complete and rapid analysis, revolutionizing the screening process in the pharmaceutical industry. With the timsTOF MALDI PharmaPulse system, researchers and scientists have access to a powerful tool that enhances productivity and accuracy, ultimately driving drug discovery and development advancements.
The reagents and consumables segment accounted for the largest revenue share of 89.12% in 2023. The segment is also expected to expand at the fastest growth rate over the forecast period. The segment's growth is driven by the easy availability and frequent purchase of screening products for donors and recipients. Moreover, the market is propelled by the wide range of blood grouping, typing, and donor screening reagents, kits, and assays offered by North American and local manufacturers.
Additionally, the expanding product portfolio caters to the diverse needs of healthcare facilities, further fueling the growth of the segment in the regional bloodstream infection testing market. For instance, in March 2023, Accelerate Diagnostics, Inc., an in-vitro diagnostics company, launched the Accelerate Arc system. It comprises the Accelerated Arc Module and blood culture (BC) kit, an automated path for the accurate and rapid microbial recognition of positive blood cultures.
The blood culture segment accounted for the largest revenue share of 75.81% in 2023 and is expected to witness the fastest CAGR over the forecast period. Blood culture testing has continued to evolve with technological advancements. The introduction of automated blood culture systems and faster detection methods have enhanced result efficiency and turnaround time, further cementing the segment’s dominance.
For instance, in October 2023, BD, a global medical technology company, and Magnolia Medical Technologies, Inc. entered a commercial agreement. The collaboration aims to assist U.S. hospitals in reducing blood culture contamination, enhancing testing accuracy, and ultimately improving clinical outcomes. Therefore, such initiatives with effective tools and technologies enhance the reliability and efficiency of blood culture testing, thereby boosting the demand for such methods.
Moreover, the blood culture segment is expected to experience growth due to the increasing number of cancer cases, bloodstream infections (BSIs), and sepsis. For instance, in June 2021, Accelerate Diagnostics, a biotech company based in Tucson, Arizona, USA, was granted funding of USD 578,000 by CARB-X. The funds are specifically allocated for developing innovative fiber optic technology aimed at diagnosing sepsis or assessing the risk of sepsis. This financial support signifies a significant opportunity for the company to advance its sepsis diagnostic capabilities and contribute to improving patient outcomes.
The PCR segment held the largest revenue share of 60.7% in 2023 in the North America bloodstream infection testing market and is expected to expand at the fastest CAGR over the forecast period. The introduction of technologically advanced PCR tests, government initiatives, increasing prevalence of targeted diseases, and application expansion of existing technologies are expected to drive segment growth over the forecast period.
For instance, PLEX-ID (Abbott Molecular) is an advanced multiplex real-time automated PCR system with amplicon product detection using ESI MS technology. This innovative solution enables rapid and accurate genotypic characterization of various pathogens, including bacteria, fungi, viruses, and parasites within a given sample, such as cultures or whole blood. By utilizing broad-range primers targeting pathogen groups instead of specific species, PLEX-ID provides comprehensive and efficient identification capabilities. This advanced technology strengthens diagnostic capabilities in infectious disease management, offering businesses a valuable tool to enhance patient care and streamline laboratory workflows, thereby fueling segment growth.
The hospital and diagnostic centers segment accounted for the largest revenue share of 45.85% in 2023 and is expected to witness the fastest CAGR from 2024 to 2033. Hospitals often have R&D departments dedicated to studying bloodstream infections and developing new diagnostic tools, therapies, and preventive strategies. Their expertise and resources contribute to advancements in the field, further solidifying their position in the bloodstream infection testing market. Hospitals also possess advanced healthcare infrastructure, including well-equipped laboratories, diagnostic facilities, and skilled healthcare professionals. This allows for efficient diagnosis, monitoring, and treatment of bloodstream infections, leading to better patient outcomes.
Moreover, hospitals frequently collaborate with medical device manufacturers, pharmaceutical companies, and diagnostic companies to develop and test innovative solutions for bloodstream infection management. These collaborations ensure the availability of advanced products and technologies within the hospital setting, strengthening their dominance in the market. In addition, advanced infrastructure, infection control measures, research capabilities, and collaborations with industry contribute to their dominant position in the bloodstream infection testing market in the region.
The U.S. dominated the regional market for bloodstream infection testing and accounted for the largest revenue share of 81.71% in 2023. This is due to the increasing awareness, favorable reimbursement policies, and increasing strategic initiatives and product launches by the major companies operating in the country. In October 2023, BD, a global medical technology company, and Magnolia Medical Technologies, Inc. entered a commercial agreement. The collaboration aims to assist U.S. hospitals in reducing blood culture contamination, enhancing testing accuracy, and ultimately improving clinical outcomes.
Therefore, such initiatives with effective tools and technologies enhance the reliability and efficiency of blood culture testing, thereby boosting the demand for such testing methods in the region. Canada is expected to witness the fastest CAGR over the forecast period, owing to the increasing demand for early detection of infections and new product launches. Additionally, increasing cases of health-associated infections, including bloodstream infections, are anticipated to drive the country's growth over the coming years.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the North America bloodstream infection testing market
Product
Sample Type
Technology
End-user
Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers